Register

General Rheumatology   

Questions discussed in this category

How do you approach management of Adult Onset Still's disease in a patient with ongoing fatigue and inflammatory joint pain despite methotrexate, colchicine, canakinumab and tocilizumab?
Heritable autoinflammatory gene testing negative. Is there a role for TNF inhibitor?
1 Answer available
How will you approach tapering sarilumab in patients with PMR in remission?
After what interval of sustained remission will you attempt to taper, and will you do so by first widening the dosing interval?
3 Answers available
What is your approach to working up diarrhea in an immunocompromised patient?
1 Answer available
What are your top takeaways from ACR Convergence 2023?
2 Answers available
What treatment options do you recommend in a patient with idiopathic granulomatous mastitis that has not improved on steroids and methotrexate?
1 Answer available
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
2 Answers available
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
1 Answer available
How do you approach a patient on anti-TNF with positive Quantiferon (previously negative) with negative chest x-ray and no symptoms?
3 Answers available
At what point do you consider a patient to have relapsing PMR?
How much cummulative prednisone exposure do you tolerate and how many attempts at tapering will you pursue before considering addition of a steroid sp...
2 Answers available
What is your approach to evaluation in patients who present with erythromelalgia?
1 Answer available
How will you approach drug sequencing in patients with PMR given the SAPHYR data?
Will you initiate sarilumab as a first steroid sparing agent or will you still pursue a DMARD such as methotrexate before initiating sarilumab? To wha...
2 Answers available
How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?
2 Answers available
What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?
Do you universally perform baseline DEXA and Hgb A1C? How often are you obtaining routine labs?
2 Answers available
How do you manage a patient with cervical cancer who has FDG uptake in bilateral ischial tuberosities with lytic areas on CT correlate, and also has a history suspicious for untreated polymyalgia rheumatica with chronic symptoms in the same anatomic locations?
Cervical cancer FIGO stage IIIC2. Bloodwork shows elevated ESR and CRP. 
4 Answers available
What is your approach to evaluation and management of a patient with Blau Syndrome and GI manifestations?
1 Answer available
How do you differentiate active vasculitis from pregnancy complications such as pre-eclampsia and HELLP in a patient with AAV?
3 Answers available
How do you approach the timing of Rituximab during pregnancy in a patient with life or organ threatening autoimmune disease?
3 Answers available
Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?
1 Answer available
Would you feel comfortable adding benlysta to patient already taking both mycophenolate and tacrolimus (and hydroxychloroquine) who still has some evidence of active lupus nephritis?
1 Answer available
In patients taking biologics who are planning joint replacement and are known MRSA carriers do you perform decolonization prior to surgery?
1 Answer available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
1 Answer available
Do you stop TNF inhibitors during the third trimester of pregnancy?
2 Answers available
At what point would you consider anticoagulation in a pregnant patient with lupus nephritis and non-nephrotic range proteinuria?
2 Answers available
What is your approach to patients with severe sicca symptoms and history of B Cell lymphoma?
Patient has received treatment with Rituximab and is taking hydroxychloroquine.
1 Answer available
What is your approach to tapering chronic steroids in patients who are at high risk of HPA suppression?
For example, patients who have been maintained on 5mg of prednisone for years without previous tapering attempts and the rheumatic disease is not acti...
1 Answer available
In a patient who is on oral DMARDs and has received 3 COVID boosters, but recently had COVID-19 infection, is bivalent booster still recommended 3 months later?
3 Answers available
How do you approach pre-conception counseling in males who are on medications for which there is limited or no data such as Jak inhibitors, apremilast, or belimumab?
2 Answers available
Do you hold rituximab for cataract surgery?
If so, when do you recommend timing for the cataract surgery? 
3 Answers available
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having a chronic foot ulceration?
2 Answers available
How would approach the management of a patient with significantly positive anticardiolopin and beta 2 glycoprotein antibodies in the absence of any clotting (including obstetric) history but with significant thrombocytopenia (but no other features of active connective tissue disease)?
1 Answer available
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
1 Answer available
How do you approach work up for underlying rheumatologic disease in patients referred for chronic urticaria?
1 Answer available
Have you seen drug induced SCLE from IL-17 inhibitors?
And if so, what is your approach to the diagnosis?
1 Answer available
How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?
Patient is asymptomatic. Labs showed +P-ANCA 1:160. Negative MPO and PR3.
2 Answers available
Is polymyalgia rheumatica associated with increased toxicity for lung SBRT?
1 Answer available
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
1 Answer available
If a patient with relapsing remitting MS has comorbid Sjogren's syndrome and is on hydroxychloroquine (Plaquenil), how does that impact choice of DMT for MS?
1 Answer available
In a patient with active spondylarthritis and uveitis who cannot take TNF inhibitors, what is your next agent of choice?
1 Answer available
Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?
 Patient is on antibiotics for chronic spinal hardware infection.
1 Answer available
What is your approach to continuing or altering therapy when inheriting a patient with combined biologic immunosuppression that is in excess of guidelines?
How do you approach de-escalation or justify therapy maintenance? Do you have tiers of medications that you attempt to de-escalate first? In one parti...
1 Answer available
Do you continue methotrexate in patients with inflammatory arthritis who develop non-melanomatous skin cancer while on therapy?
1 Answer available
Would you have a patient temporarily discontinue methotrexate while receiving a FAST or FAST FORWARD regimen for breast irradiation?
The patient is on a dose of 22 mg of methotrexate weekly for severe rheumatoid arthritis. If you would discontinue the methotrexate, how long would y...
1 Answer available
What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?
ANC <500
1 Answer available
What is your approach to a patient with IgG4RD with past pulmonary involvement (biopsy proven) managed with steroids alone, now with new hematuria/proteinuria, but stable renal function?
Would you obtain renal biopsy first or treat with additional immunosuppression for suspected renal involvement related to IgG4?
3 Answers available
How do you monitor patients with incidentally found high titer anti-smooth muscle antibodies without stigmata of liver disease?
2 Answers available
How do you manage patients with systemic sclerosis and chronic thrombotic microangiopathy on renal biopsy, but no other evidence of scleroderma renal crisis?
Patient with nephrotic range proteinuria, but there is no evidence of active TMA on renal biopsy.
1 Answer available
Do you find MRI helpful to differentiate early erosive OA from psoriatic arthritis when early X-ray changes in both conditions may be hard to distinguish?
1 Answer available
What is your approach to management of elevated liver enzymes in patients who recently started treatment with tocilizumab?
1 Answer available
How do you approach dosing of anakinra in MAS?
1 Answer available
What is your approach to evaluating a patient with known rheumatologic disease and elevated free kappa:lambda ratio, but no evidence of monoclonal immunoglobulins?
1 Answer available
What is your approach to rheumatologic disease management during the current methotrexate shortage? 
2 Answers available
How long would you wait to start another biologic agent after Rituximab administration in patients with dermatomyositis and refractory inflammatory arthritis (intolerant to traditional DMARDs)?
Patient with dermatomyositis on rituximab with refractory inflammatory arthritis. Intolerant of traditional DMARDs such as methotrexate, leflunomide, ...
1 Answer available
Would you consider re-irradiation for recurrence of Dupuytren's Contracture?
It's been 5+ years after the first course. If you decide to re-irradiate what dosing schema would you use?
2 Answers available
Do you use conventional DMARDs aside from methotrexate to prevent anti-drug antibody development for patients on infliximab?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Etanercept + Methotrexate.
3 Answers available
How would you manage tubulointerstitial nephritis and renal tubular acidosis (RTA) in a patient with Sjogren's who is pregnant?
2 Answers available
What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?
1 Answer available
How do you approach follow up of young patients with isolated +ANA, but no current clinical signs or symptoms of SLE?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Antibodies Before SLE.
6 Answers available
What is your approach to elevated CK in patients without clinical or serologic evidence of immune mediated myopathy?
1 Answer available
Does synovial biopsy provide diagnostic value in undifferentiated inflammatory arthritis?
Apart from ruling out malignancy or infection?
1 Answer available
Is there any clinical benefit in referring patients with SLE or Sjogren's with cognitive impairment for neuropsychological testing?
How do you differentiate symptoms related to centralized pain syndrome from possible cognitive dysfunction?
2 Answers available
How do you counsel patients regarding alcohol intake when prescribing DMARDs other than methotrexate?
Such as Leflunomide, Sulfasalazine, Mycophenolate or Azathioprine, since all of these medications have potential to cause liver enzyme elevation and i...
1 Answer available
How do you approach management of patients with active RA and recurrent non-severe C.diff?
(Patient with active RA despite hydroxychloroquine)
1 Answer available
How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?
In what cases do you discontinue the medication?
2 Answers available
How long do you expect gastrointestinal side effects of leflunomide to persist after stopping treatment?
2 Answers available
How do you approach patients referred for C1-2 pannus/erosions without clinical findings or serologies consistent with RA or CPPD arthropathy?
2 Answers available
Do you generally recommend starting nintedanib prior to immunosuppressive therapy in a patient with CTD-ILD?
Do you prefer to start with nintedanib and then add immunosuppressive agents, or give a trial of immunosuppressive medication first, then add nintedan...
4 Answers available
What would be the main indications for opting for biosimilars over an original biologic, outside of insurance barriers?
Are there any instances where you would prefer a biosimilar rather than the reference product? 
2 Answers available
Would you use TNF inhibitors in patients with features of SLE, but active peripheral and axial spondylarthritis?
Patient with sacroiliitis on imaging, failure of two NSAIDs.
2 Answers available
How do you decide when to obtain genetic testing for suspected autoinflammatory conditions in adults?
1 Answer available
When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?
Do you attempt to taper fully or maintain at a low dose?
2 Answers available
How do you approach the workup for a patient with persistently elevated inflammatory markers (CRP and ESR) whose history and exam do not point to a clear cause?
4 Answers available
How do you approach biologic initiation in patients with inflammatory arthritis and repeatedly indeterminate Quantiferon?
2 Answers available
Do you combine oral and topical NSAIDs for pain relief?
2 Answers available
Would you be comfortable using a JAK inhibitor in a patient with baseline thrombocytosis?
Would the etiology of the thrombocytosis play a role in your decision-making?
1 Answer available
Do you consider anti-viral prophylaxis in patients taking JAK inhibitors who have recurrent uncomplicated Zoster infection, but would prefer not changing therapy?
1 Answer available
What target do you utilize in clinical practice for defining disease remission in RA?
This question is part of a collaboration with RheumMadness and is specifically in reference to:BeSt TrialMeasurement of Patient Outcomes in Arthritis
1 Answer available
Do you recommend chlorhexidine mouth rinse for prophylaxis against oral complications in patients undergoing dental work who are immunosuppressed?
1 Answer available
Would you consider re-challenging a patient with rituximab after they experienced delayed neutropenia?
In a patient for whom rituximab is the best option for their disease management. 
2 Answers available
How do you differentiate the normal feeding vessel to the lunate from an erosion or power doppler signal on ultrasound?
1 Answer available
How do you counsel patients about the malignancy risk associated with azathioprine?
1 Answer available
Do you recommend patients continue folic acid for a few weeks after methotrexate discontinuation?
1 Answer available
How do you approach the usage of hydroxychloroquine in patients with rheumatologic conditions and baseline cardiomyopathy or heart failure?
1 Answer available
Do you continue to utilize ESR and CRP in patients on tocilizumab?
2 Answers available
How do you approach the use of hydroxychloroquine in patients with a history of visual field defect from another cause such as macular degeneration or diabetic retinopathy?
3 Answers available
How do you approach a negative ANA and positive dsDNA in patients who have arthralgia, hair loss or other UCTD features?
5 Answers available
Is there utility in obtaining pericardial fluid autoimmune labs such as ANA or RF in patients with recurrent idiopathic pericardial effusions, but no other clinical or serologic evidence of rheumatic disease?
2 Answers available
How do you approach evaluation of hypocomplementemia in a patient with arthralgias and a history of Hodgkin's lymphoma treated in the past?
ANA and ENA negative
1 Answer available
How do you manage severe Raynaud's phenomenon with ulceration in scleroderma patients that is refractory to oral agents (CCBs, PDEis, ARBs, and ERAs)?
2 Answers available
Is there any role of sympathectomy in Raynaud’s disease?
2 Answers available
How do you approach oral DMARD and/or biologic selection in patients with RA and a history of gastric bypass or whom are planning bariatric surgery?
1 Answer available
How do you counsel patients regarding contraception use while taking mycophenolate/mycophenolic acid?
2 Answers available
Would you consider use of belimumab in a patient with SLE with recurrent anterior uveitis who failed other treatment options?
Patient failed topical ocular therapies, methotrexate, azathioprine.
2 Answers available
In which clinical scenarios is relying on the urine protein-to-creatinine ratio as a measure of proteinuria unreliable, and interpretations should be made looking at urine protein and urine creatinine separately?
1 Answer available
How do you manage a patient with progressive cerebellar ataxia and positive cardiolipin antibodies?
Do you wait 12 weeks for confirmation to begin treatment if patient is declining?
1 Answer available
What is your approach to patients who present with unilateral Raynaud's?
3 Answers available
Do you typically see peripheral neuropathy in patients with castleman syndrome?
2 Answers available
How do you manage a patient with giant cell arteritis treated with weekly tocilizumab and low dose glucocorticoid who develops sudden vision loss?
2 Answers available
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
2 Answers available
What is your approach to the use of NSAIDs in patients with a history of gastric sleeve/bypass?
1 Answer available
How do you interpret elevations in ESR and CRP in the setting of increased BMI?
4 Answers available
When do you consider discontinuing Pegloticase in a patient with tophaceous gout who has had excellent response to therapy?
1 Answer available
What is your approach to patients with PMR on steroids over a prolonged initial course who start to experience weakness concerning for steroid myopathy?
2 Answers available
Do you discontinue or adjust azathioprine when a patient develops elevated MCV after starting it?
When it seems fairly certain that this is a drug effect is it something that can just be monitored or requires a change in approach?
2 Answers available
What is your approach to timing of medications like Rituximab and Cyclophosphamide around plasmapheresis in patients on daily PLEX?
4 Answers available
What is the appropriate management of arthralgias associated with bosutinib?
1 Answer available
How do you approach treatment of RA with methotrexate in a patient with treated Hepatitis C and normal liver function?
1 Answer available
How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?
1 Answer available
Would you consider continuing a biologic for difficult to control autoimmune disease in a patient with a recent diagnosis of a surgically curable solid malignancy?
Would you favor the use of any particular biologics over others?
1 Answer available
Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?
1 Answer available
What are your top takeaways from ACR 2022?
4 Answers available
How do you approach the continued use of TNF inhibitors in a patient with inflammatory arthritis who develops a positive dsDNA without clinical evidence of drug-induced lupus?
2 Answers available
What is your approach to tapering therapy in a patient with recurrent pericarditis now well-controlled on rilonacept?
2 Answers available
How do you approach Covid vaccine counseling in patients with rheumatic disease and history of pericarditis/serositis?
1 Answer available
Do you recommend continuous antibiotic prophylaxis for patients on complement inhibitors such as eculizumab?
Do you just use antibiotic prophylaxis if therapy is started prior to meningococcal vaccination?
3 Answers available
How do you approach the workup of a patient with incidentally found pachymeningitis?
1 Answer available
What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?
1 Answer available
How do you assess potential fetal harm in patients who have unplanned pregnancy while taking teratogenic medications?
1 Answer available
When considering the use of DOACs in APLS, does the number of positive APLS antibodies influence your decision?
2 Answers available
What is your treatment algorithm for management of retroperitoneal fibrosis that does not respond to high-dose glucocorticoids?
1 Answer available
When would you consider rituximab as induction therapy in IgG4-related disease?
4 Answers available
Do you avoid intra-articular and bursa/tendon sheath corticosteroid injections in patients with a history of avascular necrosis?
2 Answers available
When would you consider utilizing bone scintigraphy in the assessment of inflammatory arthritis?
1 Answer available
How do you manage nausea in the setting of hydroxychloroquine use?
1 Answer available
Do you utilize ethyl chloride spray prior to steroid injections?
1 Answer available
Would you intensify therapy in IgG4 related disease based solely on a persistently significantly elevated IgG4 level when all disease manifestations and inflammatory markers have normalized?
1 Answer available
In patients who develop a VTE, what conditions do you consider as persistent, provoking risk factors, and at what point are they controlled enough to stop anticoagulation?
I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...
1 Answer available
How would you manage polymyalgia rheumatica refractory to prednisone, methotrexate and tocilizumab?
Patient has no current evidence of underlying vasculitis or malignancy.
2 Answers available
How do you evaluate patients who have panuveitis without any systemic symptoms?
1 Answer available
Do you refer all patients with a Beighton score over 5 to genetics for further assessment?
2 Answers available
What is your approach to monitoring for hepatic fibrosis in chronic methotrexate use?
Do you frequently order liver biopsies for these patients?
1 Answer available
Would you favor stopping hydralazine in a patient requiring it for refractory hypertension if they also have a high titer ANA in the absence of any SLE symptoms?
2 Answers available
What is the role of synovectomy in the diagnosis and management of patients with inflammatory arthritis?
1 Answer available
What is your approach to the workup for an underlying systemic condition in a patient presenting with retinal vasculitis?
1 Answer available
How do you evaluate livedo reticularis (not livideo racemosa)?
Does your evaluation hinge on nonresolution with warming? How extensive is your workup?
1 Answer available
When do you consider vascular imaging in patients with Raynaud's and what type of imaging modalities do you utilize?
1 Answer available
How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?
2 Answers available
What is your approach to workup for an underlying disorder in a patient with bilateral hip avascular necrosis?
1 Answer available
How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?
Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...
2 Answers available
What is the role of non-prednisone oral glucocorticoids in the management of systemic rheumatologic disease?
Such as oral methylprednisolone, dexamethasone, prednisolone, etc.
1 Answer available
Which medications have the lowest risk of tuberculosis reactivation in patients with uncertain tuberculosis history and active rheumatologic disease?
2 Answers available
What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?
1 Answer available
Does calcinosis appear differently in patients with dermatomyositis compared to systemic sclerosis?
1 Answer available
Do you treat fibromyalgia in your practice or do you refer back to PCP after ruling out autoimmune inflammatory pathology?
3 Answers available
How do you utilize methotrexate and/or hydroxychloroquine in the setting of limited scleroderma/CREST?
1 Answer available
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
1 Answer available
Is there a role for regular hepatitis and TB screening in patients on chronic immunosuppressive therapy in the absence of new risk factors or exposures?
1 Answer available
Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?
1 Answer available
How do you think about biologic use in patients with underlying HIV infection?
2 Answers available
Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?
1 Answer available
What is your approach to evaluation of underlying autoimmune disease in patients with bilateral scleromalacia?
1 Answer available
How do you treat post-IVIG headache that is not responsive to Tylenol or NSAIDs?
Specifically, how do you treat the delayed headache, not the headache that develops during the infusion where pre-hydration and slowing down the rate ...
4 Answers available
Is there a role for prednisolone over prednisone in rheumatic patients with hepatic impairment?
1 Answer available
When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?
How do you decide if it may be safe to continue immunotherapy?
1 Answer available
Given the "LDL Paradox", in which RA patients with the highest levels of inflammation can have ultra-low levels of LDL (<70), how do you approach initiation of statin therapy in these patients?
Dr. Charles-Schoeman presented data at ACR 21 showing that, paradoxically, there is a U-shaped relationship between inflammation and LDL levels in pat...
1 Answer available
Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?
1 Answer available
When would you consider checking JC virus prior to initiating biologic therapy?
1 Answer available
How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?
Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?
2 Answers available
What is your management approach for patients with Adult Onset Still's who are planning pregnancy?
1 Answer available
What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2 Answers available
How do you diagnose and treat patients who develop uveitis while on bisphosphonate therapy for osteoporosis?
Are there specific features that suggest drug-induced uveitis versus de novo uveitis?
1 Answer available
How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?
1 Answer available
What is your differential for a patient presenting with multiple digits affected by flexor tenosynovitis, dupuytren's, and no evidence of peripheral inflammatory arthritis?
1 Answer available
How do you approach folate supplementation for methotrexate-related side effects?
3 Answers available
What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?
2 Answers available
Are there any specific circumstances when you would consider the use of immunosuppression for DISH?
There is some emerging evidence that there is an inflammatory component. 
1 Answer available
How would you counsel a patient who is interested in using supplements (such as fish oil or turmeric) as an adjunct to treatment of inflammatory arthritis?
3 Answers available
How do you approach the treatment of eosinophilic fasciitis refractory to glucocorticoids and methotrexate?
1 Answer available
Would you consider using a TNFi in a patient with a family history of demyelinating disease, in the absence of a personal history?
2 Answers available
How do you approach management of patients with inflammatory arthritis who are asymptomatic but develop radiographic progression?
1 Answer available
What is your threshold for number of alcoholic drinks per week before reconsidering prescribing methotrexate/leflunomide?
1 Answer available
How do you approach the use of biologics in patients with a history of Guillain-Barre syndrome?
1 Answer available
What is your approach to managing abnormal lipids in a patient on tocilizumab?
1 Answer available
How do you approach the treatment of inflammatory polyarthritis in patients with myelodysplastic syndromes?
2 Answers available
How do you approach the evaluation of patients referred for chronic lyme disease and counsel patients regarding this entity?
1 Answer available
Do you extrapolate from uveitis treatment pathways when managing other inflammatory eye conditions such as atypical serpiginous choroiditis?
2 Answers available
Do you switch to certolizumab in RA patients who are doing well on other TNFis and planning to become pregnant?
1 Answer available
How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?
1 Answer available
Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?
5 Answers available
Do you recommend shingles vaccine to all immunosuppressed patients under the age of 50 y.o.?
1 Answer available
Do you correct the synovial fluid white blood cell count for red blood cells, and if so, is there a rough approximation/equation you use?
2 Answers available
How do you approach patients with overlapping features of PMR and seronegative RA?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
Would you hold all immunosuppressive medications for the first month of LTBI treatment, or just biologics?
1 Answer available
How do you interpret a high positive RNP in the setting of a negative ANA and negative sm/RNP?
To my understanding, sm/RNP should also be positive in this situation (and one would assume a positive ANA as well)
1 Answer available
Is there an increased risk of COVID-19 in patients on immunosuppressants?
1 Answer available
Do you avoid any specific biologic therapies in HIV positive patients?
1 Answer available
What is your inflammatory arthritis differential when a patient presents with unilateral TMJ synovitis?
2 Answers available
What are examples of rheumatology quality measures that are both clinically meaningful and can be captured accurately and efficiently?
1 Answer available
Which steroid-sparing agent do you prefer to treat multi-organ Sweet's syndrome?
1 Answer available
Do you follow patients with elevated ESR/CRP if their work-up for rheumatologic etiology is unrevealing and no other cause is identified?
2 Answers available
What would be your differential for a wrist monoarthritis in an elderly female with erosions on MRI after less than 3 months of symptoms?
1 Answer available
How do you manage patients who are Hepatitis B core antibody positive/surface antigen negative and starting a biologic DMARD (other than rituximab)?
1 Answer available
Is there a role for tocilizumab in treatment of polymyalgia rheumatica in patients who do not have features of giant cell arteritis or rheumatoid arthritis?
1 Answer available
Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?
1 Answer available


Papers discussed in this category

Arthritis Rheumatol, 2016 Jan
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis and rheumatism, 1982-11
The 1982 revised criteria for the classification of systemic lupus erythematosus.
Arthritis and rheumatism, 2012-08
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
, 2019 Aug 06
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Arthritis Rheum.,
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
,
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.
Arthritis care & research, 2017-03
Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.
Clin Exp Dermatol, 2018 May 24
Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
Eur J Rheumatol, 2017 Feb 23
Management of the temporomandibular joint in inflammatory arthritis: Involvement of surgical procedures.
Rev Bras Reumatol Engl Ed, 2016 Mar 16
What rheumatologists should know about orofacial manifestations of autoimmune rheumatic diseases.
Southern medical journal, 2016-11
Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.
Annals of the rheumatic diseases, 2011-05
Lupus Atherosclerosis Prevention Study (LAPS).
Atherosclerosis, 2015 Aug 28
Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
N Engl J Med, 2020 Apr 29
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
The Journal of arthroplasty, 2008-02
Determining "true" leukocytosis in bloody joint aspiration.
N Engl J Med,
Clinical practice. Care of the asplenic patient.
Mediterr J Rheumatol, 2020 Jun 11
Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.
Clin Infect Dis,
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.
Cochrane Database Syst Rev, 2013 May 31
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
British journal of cancer, 2023 Feb 04
Use of methotrexate and risk of skin cancer: a nationwide case-control study.
Ann Rheum Dis, 2017 Mar 23
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.
Clin Pharmacokinet,
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Gut,
Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.
Arthritis and rheumatism, 2001-12
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.
J Med Food,
Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Int J Clin Pract, 2021 Apr 29
Curcumin and rheumatoid arthritis: A systematic review of literature.
Nutrients, 2020 Dec 11
Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic Literature Review.
Current rheumatology reports, 2009-10
Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis.
Radiology,
Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH).
Curr Rheumatol Rep, 2021 Jan 26
Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component.
Kidney international, 2009-12
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis.
Clinical journal of the American Society of Nephrology : CJASN, 2010-07
Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.
Journal of the American Society of Nephrology : JASN, 2010-08
Comparison of different measures of urinary protein excretion for prediction of renal events.
Am J Kidney Dis, 2016 Sep 16
Timed Urine Collections for Albumin and Protein: "The King Is Dead, Long Live the King!".
J Rheumatol, 2004 Aug
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis.
N Engl J Med, 2021 Aug 04
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Curr Opin Rheumatol,
Retinal vasculitis.
BMJ Open, 2019 May 05
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
Rheumatology (Oxford),
Five successful pregnancies with antenatal anakinra exposure.
Z Rheumatol,
[IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].
Journal of neurovirology, 2018-06
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Blood Adv,
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
Annals of the rheumatic diseases, 2012-08
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis Rheumatol, 2020 Jan 07
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
J Rheumatol, 2013 Nov 15
Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.
Arthritis Res Ther, 2005 Mar 01
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
JAMA Ophthalmol, 2015 Oct
Association of systemic lupus erythematosus with uveitis.
JAMA, 2022 Oct 11
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.
Front Immunol, 2021 May 14
A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.
J Rheumatol, 2019 Apr 01
Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry.
RMD Open,
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.
Curr Med Chem,
Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.
Pathology, 2017 Mar 11
The role of interleukin-17A in the pathogenesis of kidney diseases.
Lancet,
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Annals of the rheumatic diseases, 2015-06
Rituximab for IgG4-related disease: a prospective, open-label trial.
Neth J Med,
The treatment outcomes in IgG4-related disease.
Medicine (Baltimore),
Therapeutic approach to IgG4-related disease: A systematic review.
Ann Rheum Dis, 2016 Oct 03
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
ACR Open Rheumatol, 2021 Aug 25
Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
Arthritis Res Ther, 2021 Mar 22
Vision loss in patients with giant cell arteritis treated with tocilizumab.
J Orthop Translat, 2020 Jan 06
Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version).
Annals of internal medicine, 2018-01-16
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
J Immunother Cancer,
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Autoimmun Rev, 2012 Nov 30
Immunogenicity and autoimmunity during anti-TNF therapy.
Arthritis Rheum,
Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
Arthritis care & research, 2014-08
Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.
Intern Med J, 2022 Mar 16
Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.
Ann Rheum Dis, 2016 Feb 17
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
Support Care Cancer, 2019 Dec 13
Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.
Int J Surg Case Rep, 2020 Nov 22
Destructive Osteonecrosis of the Femoral Head After a Single Intra-Articular Corticosteroid Injection: A Report of Two Cases.
Eur J Orthop Surg Traumatol, 2019 Sep 19
Avascular necrosis of the femoral head after single steroid intra-articular injection.
Annals of the rheumatic diseases, 2019-10
EULAR recommendations for the management of antiphospholipid syndrome in adults.
J Thromb Haemost, 2020 Nov 29
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Front Cardiovasc Med, 2021 Aug 03
Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.
Medizinische Klinik (Munich, Germany : 1983), 2002-11-15
[Prevalence of circulating autoantibodies in healthy individuals].
Journal for scientific research. Medical sciences, 2001 Apr
Occurence of autoantibodies in healthy Omani individuals.
Clin Microbiol Infect, 2018 Feb 07
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
Arthritis & rheumatology (Hoboken, N.J.), 2018-03
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
N Engl J Med, 2020 Nov 16
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ann Rheum Dis, 2022 Sep 22
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Rheumatology (Oxford), 2014 Sep 16
Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Open access rheumatology : research and reviews, 2016
Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.
PET Clin, 2020 Feb 11
18F-Fluorodeoxyglucose PET/Computed Tomography in the Diagnosis and Monitoring of Giant Cell Arteritis.
Rheumatology (Oxford), 2022 Jul 22
PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis.
Arthritis and rheumatism, 2008-09
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014-12
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Curr Rheumatol Rep, 2022 Feb 15
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
Arthritis Care Res (Hoboken), 2017 Dec
Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis.
JAMA, 1999 Dec 08
Elevated C-reactive protein levels in overweight and obese adults.
Reumatologia, 2020 Feb 28
The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis - a cross-sectional study.
Pediatr Blood Cancer, 2021 Oct
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Int. J. Radiat. Oncol. Biol. Phys.,
Radiotherapy optimization in early-stage Dupuytren's contracture: first results of a randomized clinical study.
The New England journal of medicine, 2003-10-16
Development of autoantibodies before the clinical onset of systemic lupus erythematosus.
Rheumatology (Oxford, England), 2018-09-01
The SLE-key test serological signature: new insights into the course of lupus.
Lupus, 2021 Jan 05
Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.
Arthritis Rheumatol, 2018 Jun 27
Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.
J Manag Care Spec Pharm, 2022 Jul 01
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
Diagnostics (Basel), 2021 Sep 01
Anti-DFS70 Antibodies for Differentiating Systemic Autoimmune Rheumatic Disease in Patients with Positive ANA Tests: A Systematic Review and Meta-Analysis.
Front Immunol, 2021 May 27
Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond.
Arthritis Rheumatol, 2020 Apr
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
Immunol Invest, 1985 Jun
Specificity of the Crithidia luciliae method for detecting anti-DNA antibodies. Effect of absorption for lipoproteins.
Int J Environ Res Public Health, 2021 Aug 01
Relationship of Hydroxychloroquine and Ophthalmic Complications in Patients with Type 2 Diabetes in Taiwan.
Arthritis Care Res (Hoboken), 2023 Feb 10
Occam's Razor Dulled: A Curious Case of Dyspnea in a 70-Year-Old.
J Am Dent Assoc, 2016 Jan 05
Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention.
Eur J Radiol, 2020 Jan 17
Ultrasound characterization of pseudoerosions and dorsal joint recess morphology of the hand and wrist in 100 asymptomatic subjects.
Joint Bone Spine, 2019 Jan 31
Ultrasonographic criteria for the diagnosis of erosive rheumatoid arthritis using osteoarthritic patients as controls compared to validated radiographic criteria.
Arthritis Rheumatol, 2020 Sep 6
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Arthritis and rheumatism, 2011-03
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
The Journal of rheumatology, 2013-05
Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Arthritis & rheumatology (Hoboken, N.J.), 2017-10
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Arthritis Rheum, 2004 Oct
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Ther Adv Musculoskelet Dis, 2020 Nov 24
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.
Cleveland Clinic journal of medicine, 2016-01
Approach to asymptomatic creatine kinase elevation.
The British journal of dermatology, 2019-11
Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice.
J Am Acad Dermatol, 2020 Sep 04
Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective.
Rheumatology (Oxford),
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
Medicine (Baltimore), 2016 Aug
Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range.
BMJ, 2021 Jun 23
Investigating raised creatine kinase.
Arthritis and rheumatism, 2010-05
Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests.
Ann Clin Transl Neurol, 2020 Jul 06
Cognitive impairment in patients with Neuro-Sjögren.
Lupus, 2023 Apr 10
In-person versus virtual administration of the American College of Rheumatology gold standard cognitive battery in systemic lupus erythematosus: Are they interchangeable?
Lupus Sci Med, 2022 Jan
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus.
Nat Rev Nephrol, 2015 Nov 16
Renal involvement in primary Sjögren syndrome.
Arthritis & rheumatology (Hoboken, N.J.), 2018-06
Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.
Nat Med, 2022 Jun
Inching closer to precision treatment for rheumatoid arthritis.
Nat Med, 2022 May 19
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Curr Opin Rheumatol, 2013 May
New learnings on the pathophysiology of RA from synovial biopsies.
Arthritis Res Ther, 2014 Apr 30
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
Annals of clinical and laboratory science, 2008
Nephrotic range proteinuria: rare manifestation of scleroderma renal crisis.
International journal of general medicine, 2019 Sep 02
Renal pathology and clinical associations in systemic sclerosis: a historical cohort study.
Ophthalmology and therapy, 2023 Aug 21
Cataract Surgery Outcomes in Patients with Non-ocular Autoimmune Disease.
Ann Rheum Dis, 2020 Jan
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.
Mediterranean journal of rheumatology, 2022 Mar 31
Clinical Phenotype and Mechanisms of Leukopenia/Neutropenia in Patients with Primary Sjögren's Syndrome.
Annals of the rheumatic diseases, 2018-09
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Arthritis & rheumatology (Hoboken, N.J.), 2019-02
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
RMD open, 2020 Feb
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
The New England journal of medicine, 2014 Jun 05
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Trials, 2022 Sep 05
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Clinical and experimental dermatology, 2021 Mar 09
Brodalumab-induced subacute cutaneous lupus erythematosus.
JAAD case reports, 2019 Mar 01
Ustekinumab-induced subacute cutaneous lupus.
Dermatologic therapy, 2020 May 03
Secukinumab-induced subacute cutaneous lupus erythematosus.
The Journal of allergy and clinical immunology, 2012 Feb 14
Chronic urticaria and autoimmunity: associations found in a large population study.
Blood, 2022 Jun 23
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
Best practice & research. Clinical rheumatology, 2019 Dec 19
Antiphospholipid syndrome.
Blood, 2011-02-03
Pregnancy outcomes after maternal exposure to rituximab.
Arthritis Care Res (Hoboken), 2020 Apr
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
Journal of clinical medicine, 2023 Feb 24
Kidney Biopsy in Pregnant Women with Glomerular Diseases: Focus on Lupus Nephritis.
Chest, 2021 Feb
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
The ocular surface, 2015 Jan 15
Clinical guidelines for management of dry eye associated with Sjögren disease.
Arthritis and rheumatism, 2011-12
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
N Engl J Med,
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Arthritis Rheumatol, 2017 Apr 07
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Lancet (London, England), 2011 Feb 04
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Annals of internal medicine, 2004-10-05
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.
The New England journal of medicine, 2023 Oct 05
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Annals of the rheumatic diseases, 1996 Apr
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
The Journal of rheumatology, 1996 Sep
The use of methotrexate in polymyalgia rheumatica.
International journal of clinical pharmacology and therapeutics, 2021 May
Methotrexate for treating polymyalgia rheumatica: A meta-analysis of randomized controlled trials.
Annals of the rheumatic diseases, 2022 Feb 24
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
JAMA, 2022 Sep 20
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Ann Rheum Dis, 2015 Oct
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
Arthritis care & research, 2023 Aug 10
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry.
Arthritis care & research, 2023 Oct 26
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Rheumatology advances in practice, 2021 Nov 27
Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study.
Rheumatology (Sunnyvale, Calif.), 2015 May 07
Polymyalgia Rheumatica and its Association with Cancer.
Annals of the rheumatic diseases, 2013 Jul 10
Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database.
Journal of behavioral medicine, 2023 Jun 29
Self-guided digital acceptance and commitment therapy for fibromyalgia management: results of a randomized, active-controlled, phase II pilot clinical trial.

Related Topics

Copyright © 2023 theMednet
All Rights Reserved.